T 1870/21 (Crenolanib for treating flt3 mutated proliferative disorders / AROG) of 23.05.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T187021.20240523
- Date of decision
- 23 May 2024
- Case number
- T 1870/21
- Petition for review of
- -
- Application number
- 13869984.8
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS
- Applicant name
- Arog Pharmaceuticals, Inc.
- Opponent name
- HEXAL PHARMA AG
- Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 113(1)European Patent Convention R 103(1)(a)Rules of procedure of the Boards of Appeal 2020 Art 011
- Keywords
- Substantial procedural violation - (yes)
Substantial procedural violation - reimbursement of appeal fee (yes)
Remittal to the department of first instance
Remittal - fundamental deficiency in first instance proceedings (yes) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The decision under appeal is set aside.
The case is remitted to the opposition division for further prosecution.
The appeal fee is reimbursed.